Responses
Regular and young investigator award abstracts
Clinical trials in progress
432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.